Related Experiment Video
Updated: Dec 19, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung
Shuai Guo1, Liang Qiu2, Yafei Chen2
1State Key Laboratory of Reliability and Intelligence of Electrical Equipment, Hebei University of Technology, Tianjin 300130, China; Key Laboratory of Electromagnetic Field and Electrical Apparatus Reliability of Hebei Province, Hebei University of Technology, Tianjin 300130, China; Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin 300401, China.
Abstract:
To overcome the adverse effects of conventional chemotherapy for cancers, various nanoparticles based drug delivery systems have been developed. However, nanoparticles delivering drugs directly to kill tumor cells still faced with challenges, because tumors possessed adopt complex mechanism to resist damages, which compromised the therapeutic efficacy. TMEM16A/CaCCs (Calcium activates chloride channels) has been identified to be overexpressed in lung adenocarcinoma which can serve as a novel tumor specific drug target in our previous work. Here, we developed a novel dual-targeted antitumor strategy via designing a novel nano-assembled, pH-sensitive drug-delivery system loading with specific inhibitors of TMEM16A against lung adenocarcinoma. For validation, we assayed the novel dual-targeting therapy on xenograft mouse model which exhibited significant antitumor activity and not affect mouse body weight. The dual targeting therapy accomplished in this study will shed light on the development of advanced antitumor strategy.
Insights
This study introduces a novel dual-targeting nanoparticle drug delivery system for lung adenocarcinoma, effectively inhibiting tumor growth without adverse effects on mouse body weight.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Conventional chemotherapy faces challenges due to tumor resistance, compromising therapeutic efficacy.
- Nanoparticle drug delivery systems aim to improve cancer treatment but still encounter obstacles in targeting tumor cells.
- TMEM16A/Calcium-activated chloride channels (CaCCs) are overexpressed in lung adenocarcinoma, presenting a potential tumor-specific drug target.
Purpose of the Study:
- To develop a novel dual-targeted antitumor strategy for lung adenocarcinoma.
- To design a pH-sensitive, nano-assembled drug delivery system loaded with TMEM16A inhibitors.
- To evaluate the efficacy and safety of this dual-targeting therapy in a preclinical model.
Main Methods:
- Development of a novel nano-assembled, pH-sensitive drug delivery system.
- Loading the system with specific inhibitors targeting TMEM16A.
- Administration and validation of the dual-targeting therapy in a lung adenocarcinoma xenograft mouse model.
Main Results:
- The dual-targeting therapy demonstrated significant antitumor activity in the xenograft mouse model.
- The treatment did not adversely affect the body weight of the mice, indicating a favorable safety profile.
- The developed system effectively delivered TMEM16A inhibitors to lung adenocarcinoma cells.
Conclusions:
- The novel dual-targeting nano-assembled drug delivery system shows promise for treating lung adenocarcinoma.
- This strategy overcomes challenges associated with tumor resistance and conventional chemotherapy side effects.
- The findings provide a foundation for developing advanced antitumor strategies utilizing targeted nanoparticle delivery.
